Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc. (LBPH) priced its initial public offering on Mar 12, 2021 at $16.00 per share, within its $14.00–$16.00 range, raising $80M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $270.7M. Cooley advised the company and Latham & Watkins advised the underwriters.

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, formed in January 2020 by Arena Pharmaceuticals, developing medicines for neurological diseases. Its lead candidate, LP352, is an oral 5-HT2c superagonist being studied for developmental and epileptic encephalopathies such as Dravet and Lennox-Gastaut syndromes.

Status

IPO

Ticker

LBPH

Exchange

Nasdaq Global Market

Priced

Mar 12, 2021

IPO price

$16.00

Price range

$14.00–$16.00

Raised

$80M

Market cap at IPO price

$270.7M

First filed

Feb 19, 2021

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.